# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price ta...
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
– Based on results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hype...
Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based...
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Cantor Fitzgerald analyst Alethia Young reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...